MarketCap
Facebook
X
Telegram
Eiger BioPharmaceuticals ROA Ratio | EIGR
Annual ROA Ratio Eiger BioPharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -193.07 | -80.55 | -26.83 | -45.3 | -66.82 | -51.14 | -98.99 | -77.53 | -238.66 | -185.68 | -4.5 | -43.74 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.5 | -238.66 | -92.74 |
Quarterly ROA Ratio Eiger BioPharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -102.82 | -83.79 | -69.96 | -47.0 | -62.84 | -56.2 | -26.17 | -11.4 | -22.55 | -21.56 | -26.57 | -43.24 | -58.75 | -60.79 | -64.39 | -47.16 | -72.61 | -70.25 | -82.87 | -64.41 | -91.96 | -93.4 | -102.83 | -77.02 | -136.78 | -158.29 | -147.17 | -124.58 | -209.61 | -166.57 | -145.07 | -152.18 | -1456.18 | -1448.07 | -1433.89 | -1423.25 | -63.44 | -80.59 | -90.35 | -94.52 | -25.78 | -23.14 | -16.4 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -11.4 | -1456.18 | -205.96 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
1.36 | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
-10.79 | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Фармсинтез
LIFE
|
-25.57 | - | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
-40.46 | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-44.14 | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Amryt Pharma plc
AMYT
|
0.12 | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
-177.72 | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
-119.89 | - | - | $ 28.6 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
Clovis Oncology
CLVS
|
-13.62 | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
-60.54 | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-48.42 | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
23.54 | $ 8.61 | 0.16 % | $ 2.05 B | USA |
|
89bio
ETNB
|
-76.68 | - | - | $ 1.55 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-102.69 | - | - | $ 384 M | Britain |
 |
Fusion Pharmaceuticals
FUSN
|
-33.2 | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
1.33 | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
-59.31 | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
-77.9 | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
-39.47 | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
-91.86 | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
-631.8 | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
-52.7 | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
-3.76 | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
-73.69 | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
-121.19 | - | - | $ 13.1 M | Canada |
 |
Intra-Cellular Therapies
ITCI
|
-1.24 | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
-64.89 | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
-32.72 | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
-180.08 | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
-69.22 | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
-32.46 | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
-57.66 | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
19.42 | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
-63.77 | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
-83.75 | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-6.15 | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
-104.58 | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
-61.6 | - | - | $ 3.3 B | USA |
 |
NexImmune
NEXI
|
-376.36 | - | 70.13 % | $ 4.12 M | USA |
 |
9 Meters Biopharma
NMTR
|
-132.03 | - | -42.97 % | $ 1.05 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
-55.73 | - | -37.48 % | $ 476 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-686.85 | - | -19.68 % | $ 18.4 M | Canada |
 |
ObsEva SA
OBSV
|
-126.77 | - | -15.52 % | $ 10.5 M | Schweiz |
 |
Oncorus
ONCR
|
-53.18 | - | -8.54 % | $ 3.19 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
-156.23 | - | 31.87 % | $ 1.61 M | USA |
 |
Oncternal Therapeutics
ONCT
|
-107.49 | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
4.27 | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
-68.82 | - | 1.02 % | $ 90.8 M | Britain |